JPS6147833B2 - - Google Patents

Info

Publication number
JPS6147833B2
JPS6147833B2 JP55136175A JP13617580A JPS6147833B2 JP S6147833 B2 JPS6147833 B2 JP S6147833B2 JP 55136175 A JP55136175 A JP 55136175A JP 13617580 A JP13617580 A JP 13617580A JP S6147833 B2 JPS6147833 B2 JP S6147833B2
Authority
JP
Japan
Prior art keywords
group
thiobiuret
reaction
general formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP55136175A
Other languages
Japanese (ja)
Other versions
JPS5759857A (en
Inventor
Hajime Fujimura
Yasuzo Hiramatsu
Takahiro Yabuchi
Masakatsu Kuki
Katsuo Takigawa
Takatsugu Pponna
Hidekazu Myake
Akira Kajitani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Priority to JP13617580A priority Critical patent/JPS5759857A/en
Publication of JPS5759857A publication Critical patent/JPS5759857A/en
Publication of JPS6147833B2 publication Critical patent/JPS6147833B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明は新規な置換チオビウレツト化合物に関
するものである。本発明に係る置換チオビウレツ
ト化合物は一般式 (式中、R1、R2およびR3は低級アルキル基
を、R4はフエニル基、置換基としてハロゲン原
子、低級アルキル基、低級アルコキシ基もしくは
トリフルオルメチル基を有するフエニル基または
アラルキル基を意味し、XおよびYは相異なつて
酸素原子またはイオウ原子を意味する。)で表わ
される。 上記一般式(1)で示される置換チオビウレツト化
合物のR1、R2、R3で表わされる低級アルキル基
およびR4のフエニル基の置換基として表わされ
る低級アルキル基は、炭素数1〜6の鎖状あるい
は分枝状のアルキル基で、例えばメチル、エチ
ル、プロピル、イソプロピル、ブチル、ペンチ
ル、ヘキシル基等を、R4のフエニル基の置換基
の低級アルコキシ基は炭素数1〜5のアルコキシ
基で、例えばメトキシ、エトキシ、プロポキシ、
ブトキシ、ペントキシ基等を、ハロゲン原子とし
ては弗素、塩素、臭素、沃素を、アラルキル基と
してはベンジル、フエネチル基等を挙げることが
できる。 本発明の置換チオビウレツト化合物は、新規化
合物であつて、抗炎症作用、鎮痛作用、抗アレル
ギー作用、利尿作用、抗菌作用および抗けいれん
作用を有し、抗炎症剤あるいは鎮痛剤として有用
な化合物である。 本発明に係る置換チオビウレツト化合物は、例
えば下記の反応式で示されるように一般式(2)で示
される尿素あるいはチオ尿素と一般式(3)で示され
るイソシアナートあるいはイソチオシアナートを
反応させることにより合成される。 (式中、R1、R2、R3、R4、XおよびYは前記
と同一である。) 本反応における一般式(2)で示される尿素あるい
はチオ尿素と一般式(3)で示されるイソシアナート
あるいはイソチオシアナートはいずれも公知化合
物であり、その反応は通常溶媒中あるいは無溶媒
下に行われる。溶媒としては反応に関与しないも
のである限り特に限定されず、一般にエーテル、
ジオキサン、テトラヒドロフラン等のエーテル
類、ベンゼン、トルエン、キシレン等の芳香族炭
化水素類、クロロホルム、ジクロルメタン、ジク
ロルエタン等のハロゲノアルカン類が使用され
る。本反応は無触媒下でも十分進行するが、触媒
としては酸性触媒あるいは塩基性触媒を用いるこ
ともできる。酸性触媒としては、例えば塩化第二
スズ、四塩化チタン、塩化アルミニウム等のルイ
ス酸が使用され、また塩基性触媒としては例えば
水素化ナトリウム、ナトリウムアミド等が使用さ
れる。 一般式(2)で示される尿素あるいはチオ尿素と一
般式(3)で示されるイソシアナートあるいはイソチ
オシアナートおよび触媒の使用割合は適宜選択す
ればよいが、一般に等モル量程度使用するのが有
利である。反応温度も適宜選択すればよいが、一
般に−20℃〜溶媒の還流程度の温度において行な
うと有利に進行する。酸性触媒を用いた反応で
は、反応終了後、チオビウレツトと金属の錯体が
反応溶液中より沈殿してくる。これを取し、水
不混和性溶媒と、水もしくは酸性水溶液の混合液
中で混合させることにより、チオビウレツトが金
属錯体から容易に遊離される。これらは通常の分
離手段、例えば再結晶、カラムクロマトグラフイ
ー等により単離可能である。一般式(1)で示される
置換チオビウレツト誘導体の実施例は下記のとお
りであり、これらの実施例によつて得た化合物を
表1に示す。 実施例 1 5―(3―トリフルオルメチルフエニル)―
1,1,3―トリメチル―4―チオビウレツト
(化合物No.20)の合成 水素化ナトリウム(50%油性)1.44g(0.03モ
ル)を無水テトラヒドロフラン80ml中懸濁撹拌下
10℃以下で、1,1,3―トリメチル尿素3g
(0.03モル)を加え、室温にて終夜撹拌した。反
応液を0℃以下に冷却し、3―トリフルオルメチ
ルフエニルイソチオシアナート6.0g(0.03モ
ル)の無水テトラヒドロフラン10ml溶液を滴下
後、0℃以下で4時間撹拌した。終了後酢酸酸性
とし、水を加えて溶媒を減圧下留去し、エーテル
抽出後芒硝にて乾燥した。エーテルを留去し、残
渣をシリカゲルカラムクロマトグラフイー(溶媒
系;ベンゼン:アセトン=5:1)にて単離後、
エーテルより再結晶して、5―(3―トリフルオ
ルメチルフエニル)―1,1,3―トリメチル―
4―チオビウレツト6.8gを得た。(収率75%) 実施例 2〜6 化合物No.12、14、16、18、22の化合物の合成 1,1,3―トリメチル尿素とイソチオシアナ
ートとして、それぞれフエニルイソチオシアナー
ト、4―クロルフエニルイソチオシアナート、4
―メチルフエニルイソチオシアナート、4―メト
キシフエニルイソチオシアナート、ベンジルイソ
チオシアナートを使用し、実施例1と同様の操作
で合成した。 実施例 7,8 化合物No.23、24の化合物の合成 1―エチル―1,3―ジメチル尿素と、それぞ
れフエニルイソチオシアナート、ベンジルイソチ
オシアナートを使用し、実施例1と同様の操作で
合成した。 実施例 9 5―(4―クロルフエニル)―1,1,3―ト
リメチル―2―チオビウレツト(化合物No.15)
の合成 1,1,3―トリメチルチオ尿素5.9g(0.05
モル)を乾燥ジクロルエタン50mlに溶かし、4―
クロルフエニルイソシアナート7.6g(0.05モ
ル)を加えて、0℃以下に冷却し、無水塩化第二
スズ13g(0.05モル)の乾燥ジクロルエタン10ml
溶液を滴下後、室温で終夜撹拌した。その反応混
合物からの析出物を取し、ジクロルエタンにて
洗浄後、クロロホルム50mlおよび10%塩酸水溶液
40mlと混合撹拌した。有機層を分取し、水洗後芒
硝にて乾燥した。クロロホルムを留去し、残渣を
シリカゲルカラムクロマトグラフイ―(溶媒系;
クロロホルム:エタノール=10:1)にて単離
後、エーテルより再結晶し、5―(4―クロルフ
エニル)―1,1,3―トリメチル―2―チオビ
ウレツト11.2gを得た。(収率83%) 実施例 10〜13 化合物No.13,17,19,21の化合物の合成 1,1,3―トリメチルチオ尿素と、イソシア
ナートとして、それぞれフエニルイソシアナー
ト、4―メチルフエニルイソシアナート、4―メ
トキシフエニルイソシアナート、3―トリフルオ
ルメチルフエニルイソシアナートを使用し、実施
例9と同様の操作で合成した。 次に本発明化合物の抗浮腫作用、鎮痛作用およ
び急性毒性を下記の試験方法により測定したの
で、その結果を表2に示す。 抗浮腫作用 急性カラゲニン浮腫試験法〔目本薬理学雑誌、
56、575(1960)〕に従つて、Wistar系雄性ラツ
ト(体重150〜180g)各群6〜8匹を用い、一夜
絶食後、薬物100mg/Kgまたは200mg/Kgを経口投
与し、その1時間後に起炎物質(1%カラゲニン
液、0.1ml/ラツト)を足蹠皮下に注入し、以後
経時的に足容積を測定した。 抗浮腫作用は、起炎物質注入後3時間目におけ
る浮腫抑制率(%)で示した。 鎮痛作用 1 酢酸ストレツチング法 Kosterらの方法〔Federation Proceedings
18、412(1959)〕に従つて、ddy系雄性マウス
(体重20〜25g)各群6〜8匹を用い、一夜絶食
後、薬物50mg/Kg、100mg/Kgまたは20mg/Kgを
経口投与した1時間後に、0.7%酢酸を動物一匹
あたり0.2mlずつ腹腔内投与し、ストレツチング
症状を観察して抑制率(%)を求めた。 2 ハフナー変法 藤村らの変法〔京都大学化学研究所報告第25
集、36(1951)〕に従つて、ddy系雄性マウス
(体重20〜25g)各群6〜8匹を用い、一夜絶食
後、薬物100mg/Kgまたは200mg/Kgを経口投与し
た45分後に、閾値用量の塩酸モルヒネ(1.5〜2.5
mg/Kg)を皮下注射し、以後1時間のクレンメに
よる疼痛反応を観察し、抑制率(%)を求めた。 急性毒性試験 ddy系雄性マウス(体重20〜25g)を用い、一
夜絶食後、薬物を経口投与した。投与後の一般症
状は7日間観察し、投与量(mg/Kg)に対する死
亡数/一群動物数として表わした。 以上の試験において、薬物はすべて0.25%カル
ボキシメチルセルロース液中に懸濁して用いた。
The present invention relates to novel substituted thiobiuret compounds. The substituted thiobiuret compounds according to the present invention have the general formula (In the formula, R 1 , R 2 and R 3 are lower alkyl groups, R 4 is a phenyl group, and a phenyl group or aralkyl group having a halogen atom, lower alkyl group, lower alkoxy group or trifluoromethyl group as a substituent. and X and Y each independently represent an oxygen atom or a sulfur atom. The lower alkyl group represented by R 1 , R 2 , and R 3 of the substituted thiobiuret compound represented by the above general formula (1) and the lower alkyl group represented as a substituent of the phenyl group of R 4 have 1 to 6 carbon atoms. A chain or branched alkyl group, such as methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl group, etc., and a lower alkoxy group as a substituent of the phenyl group in R 4 is an alkoxy group having 1 to 5 carbon atoms. For example, methoxy, ethoxy, propoxy,
Examples of the halogen atom include fluorine, chlorine, bromine, and iodine, and examples of the aralkyl group include benzyl and phenethyl groups. The substituted thiobiuret compound of the present invention is a novel compound that has anti-inflammatory, analgesic, anti-allergic, diuretic, anti-bacterial and anti-spasmodic effects, and is a compound useful as an anti-inflammatory agent or analgesic. . The substituted thiobiuret compound according to the present invention can be obtained by, for example, reacting urea or thiourea represented by general formula (2) with isocyanate or isothiocyanate represented by general formula (3) as shown in the reaction formula below. is synthesized by (In the formula, R 1 , R 2 , R 3 , R 4 , X and Y are the same as above.) In this reaction, urea or thiourea represented by general formula (2) and The isocyanate or isothiocyanate used is a known compound, and the reaction is usually carried out in a solvent or without a solvent. The solvent is not particularly limited as long as it does not participate in the reaction, and generally includes ether,
Ethers such as dioxane and tetrahydrofuran, aromatic hydrocarbons such as benzene, toluene and xylene, and halogenoalkanes such as chloroform, dichloromethane and dichloroethane are used. Although this reaction proceeds satisfactorily even in the absence of a catalyst, an acidic catalyst or a basic catalyst can also be used as the catalyst. As acidic catalysts, for example, Lewis acids such as stannic chloride, titanium tetrachloride, aluminum chloride, etc. are used, and as basic catalysts, for example, sodium hydride, sodium amide, etc. are used. The ratio of the urea or thiourea represented by the general formula (2), the isocyanate or isothiocyanate represented by the general formula (3), and the catalyst may be selected as appropriate, but it is generally advantageous to use equimolar amounts. It is. Although the reaction temperature may be selected as appropriate, it generally proceeds advantageously when carried out at a temperature of -20°C to about reflux of the solvent. In a reaction using an acidic catalyst, a complex of thiobiuret and metal precipitates from the reaction solution after the reaction is completed. Thiobiuret is easily released from the metal complex by mixing it with a water-immiscible solvent in a mixture of water or an acidic aqueous solution. These can be isolated by conventional separation means such as recrystallization, column chromatography, etc. Examples of substituted thiobiuret derivatives represented by general formula (1) are as follows, and the compounds obtained by these examples are shown in Table 1. Example 1 5-(3-trifluoromethylphenyl)-
Synthesis of 1,1,3-trimethyl-4-thiobiuret (Compound No. 20) 1.44 g (0.03 mol) of sodium hydride (50% oily) was suspended in 80 ml of anhydrous tetrahydrofuran with stirring.
1,1,3-trimethylurea 3g below 10℃
(0.03 mol) was added and stirred at room temperature overnight. The reaction solution was cooled to below 0°C, and a solution of 6.0 g (0.03 mol) of 3-trifluoromethylphenyl isothiocyanate in 10 ml of anhydrous tetrahydrofuran was added dropwise, followed by stirring at below 0°C for 4 hours. After completion of the reaction, the mixture was acidified with acetic acid, water was added, the solvent was distilled off under reduced pressure, and the mixture was extracted with ether and dried over sodium sulfate. After distilling off the ether and isolating the residue using silica gel column chromatography (solvent system: benzene:acetone=5:1),
Recrystallized from ether to give 5-(3-trifluoromethylphenyl)-1,1,3-trimethyl-
6.8 g of 4-thiobiuret was obtained. (Yield 75%) Examples 2 to 6 Synthesis of compounds No. 12, 14, 16, 18, and 22 As 1,1,3-trimethylurea and isothiocyanate, phenylisothiocyanate and 4- Chlorphenyl isothiocyanate, 4
Synthesis was performed in the same manner as in Example 1 using -methylphenylisothiocyanate, 4-methoxyphenylisothiocyanate, and benzylisothiocyanate. Example 7, 8 Synthesis of compounds Nos. 23 and 24 Using 1-ethyl-1,3-dimethylurea and phenylisothiocyanate and benzylisothiocyanate, respectively, in the same manner as in Example 1. Synthesized. Example 9 5-(4-chlorophenyl)-1,1,3-trimethyl-2-thiobiuret (Compound No. 15)
Synthesis of 1,1,3-trimethylthiourea 5.9g (0.05
mol) in 50 ml of dry dichloroethane, 4-
Add 7.6 g (0.05 mol) of chlorphenyl isocyanate, cool to below 0°C, and add 13 g (0.05 mol) of anhydrous stannic chloride to 10 ml of dry dichloroethane.
After the solution was added dropwise, the mixture was stirred at room temperature overnight. Collect the precipitate from the reaction mixture, wash it with dichloroethane, then add 50 ml of chloroform and 10% aqueous hydrochloric acid solution.
40 ml and stirred. The organic layer was separated, washed with water, and dried with sodium sulfate. Chloroform was distilled off, and the residue was subjected to silica gel column chromatography (solvent system;
After isolation with chloroform:ethanol=10:1), recrystallization from ether gave 11.2 g of 5-(4-chlorophenyl)-1,1,3-trimethyl-2-thiobiuret. (Yield 83%) Examples 10 to 13 Synthesis of compounds No. 13, 17, 19, and 21 1,1,3-trimethylthiourea and isocyanates such as phenyl isocyanate and 4-methyl fluoride, respectively. Synthesis was performed in the same manner as in Example 9 using enyl isocyanate, 4-methoxyphenyl isocyanate, and 3-trifluoromethyl phenyl isocyanate. Next, the anti-edema effect, analgesic effect, and acute toxicity of the compound of the present invention were measured by the following test methods, and the results are shown in Table 2. Anti-edema effect Acute carrageenan edema test method [Memoto Pharmacology Journal,
56 , 575 (1960)], 100 mg/Kg or 200 mg/Kg of the drug was orally administered to 6 to 8 male Wistar rats (body weight 150 to 180 g) in each group after an overnight fast, and the drug was administered orally for 1 hour. Afterwards, a inflammatory substance (1% carrageenan solution, 0.1 ml/rat) was subcutaneously injected into the footpad, and the foot volume was measured over time. The anti-edema effect was expressed as the edema suppression rate (%) 3 hours after injection of the inflammatory substance. Analgesic effect 1 Acetic acid stretching method Koster et al.'s method [Federation Proceedings
18 , 412 (1959)], 6 to 8 male DDY mice (body weight 20 to 25 g) were used in each group, and after an overnight fast, 50 mg/Kg, 100 mg/Kg, or 20 mg/Kg of the drug was orally administered. One hour later, 0.2 ml of 0.7% acetic acid was intraperitoneally administered to each animal, and the stretching symptoms were observed to determine the inhibition rate (%). 2 Modified Hafner method Modified method of Fujimura et al. [Kyoto University Chemical Research Institute Report No. 25]
36 (1951)], using 6 to 8 male DDY mice (body weight 20 to 25 g) in each group, after an overnight fast, 45 minutes after oral administration of 100 mg/Kg or 200 mg/Kg of the drug. Threshold dose of morphine hydrochloride (1.5-2.5
mg/Kg) was injected subcutaneously, and the pain response due to the cream was observed for 1 hour thereafter to determine the suppression rate (%). Acute Toxicity Test The drug was orally administered to male DDY mice (body weight 20-25 g) after an overnight fast. General symptoms after administration were observed for 7 days and expressed as the number of deaths/number of animals per group relative to the dose (mg/Kg). In the above tests, all drugs were suspended in 0.25% carboxymethyl cellulose solution.

【表】【table】

【表】【table】

【表】【table】

Claims (1)

【特許請求の範囲】 1 一般式 (式中、R1、R2およびR3は低級アルキル基
を、R4はフエニル基、置換基としてハロゲン原
子、低級アルキル基、低級アルコキシ基もしくは
トリフルオルメチル基を有するフエニル基または
アラルキル基を意味し、XおよびYは相異なつて
酸素原子またはイオウ原子を意味する。)で表わ
される置換チオビウレツト化合物。
[Claims] 1. General formula (In the formula, R 1 , R 2 and R 3 are lower alkyl groups, R 4 is a phenyl group, and a phenyl group or aralkyl group having a halogen atom, lower alkyl group, lower alkoxy group or trifluoromethyl group as a substituent. and X and Y each independently represent an oxygen atom or a sulfur atom).
JP13617580A 1980-09-29 1980-09-29 Subsituted thiobiuret compound Granted JPS5759857A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP13617580A JPS5759857A (en) 1980-09-29 1980-09-29 Subsituted thiobiuret compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP13617580A JPS5759857A (en) 1980-09-29 1980-09-29 Subsituted thiobiuret compound

Publications (2)

Publication Number Publication Date
JPS5759857A JPS5759857A (en) 1982-04-10
JPS6147833B2 true JPS6147833B2 (en) 1986-10-21

Family

ID=15169073

Family Applications (1)

Application Number Title Priority Date Filing Date
JP13617580A Granted JPS5759857A (en) 1980-09-29 1980-09-29 Subsituted thiobiuret compound

Country Status (1)

Country Link
JP (1) JPS5759857A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0649768B2 (en) * 1985-06-06 1994-06-29 信越化学工業株式会社 Method for producing aqueous gel

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5018419A (en) * 1973-05-10 1975-02-26
JPS53127436A (en) * 1977-04-12 1978-11-07 Kumiai Chem Ind Co Ltd 1-(n,n-dialkycarbamoyl)-3-(substd, phenyl) thio-ureas and insecticides containing the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5018419A (en) * 1973-05-10 1975-02-26
JPS53127436A (en) * 1977-04-12 1978-11-07 Kumiai Chem Ind Co Ltd 1-(n,n-dialkycarbamoyl)-3-(substd, phenyl) thio-ureas and insecticides containing the same

Also Published As

Publication number Publication date
JPS5759857A (en) 1982-04-10

Similar Documents

Publication Publication Date Title
US4174397A (en) Thiazolidine derivatives
EP0053407B1 (en) New imidazolylphenyl amidines, processes for their preparation and their pharmaceutical use, and intermediates of preparation
JPH026354B2 (en)
KR850000216B1 (en) Process for preparing piperazine derivatives
JP2707936B2 (en) β-oxo-β-benzenepropanethioamide derivative
JPS58219161A (en) Novel derivatives of 1,3-dihydro-4-(1-hydroxy-2- aminoethyl)-2h-indol-2-one, salts thereof, manufacture, use as drug and composition
KR900006118B1 (en) Process for preparing 4-quinolone derivatives
US3957772A (en) Process for the preparation of 4-hydroxy-3-(5-methyl-3-isoxazolylcarbamoyl)-2-methyl-2h-1,2-benzothiazine 1,1-dioxide
JPH02178263A (en) Azaazulene derivative, production thereof and anti-allergic and anti-inflammatory containing the derivative as active component
JPS6147833B2 (en)
JPS59512B2 (en) Pyrazole -5- Onkagobutsuno Seizouhouhou
Schnur et al. Improved glucose tolerance in rats treated with oxazolidinediones
EP0326108A1 (en) Antiarthritic isoxazole-4-carboxamides
JPH0578554B2 (en)
JPS6223747B2 (en)
US3676463A (en) Oxobenzofuran carboxamides
JPS646193B2 (en)
EP0090275A2 (en) Isoxazole (5,4-b) pyridines
JPH0495071A (en) Carbamic acid derivative
EP0058009A1 (en) Novel benzanilide derivatives and pharmaceutical compositions containing them
JP2658198B2 (en) Pyranobenzotriazole derivatives
JP2579116B2 (en) Novel 4-methyl-1,3-oxazole compounds, their preparation and pharmaceutical compositions containing them
JPH02286663A (en) Azole-1-alkanamides and their production
JPH03173876A (en) New diphenylthiazole derivative
JPH0680041B2 (en) 2-Pyridylacetic acid derivative, method for producing the same, and medicament containing the same